| Summary: | Objective: To retrospectively analyze the epidemics and clinical characters of inpatients and outpatients due to chronic hepatitis B (CHB) and liver cirrhosis, hoping to provide references for the prevention and treatment of CHB and liver cirrhosis.Methods: Data were retrospectively analyzed, such as the number of inpatients and outpatients within 10 years, mortality, morbidity of liver failure, classification of CHB and liver cirrhosis, and the number of patients receiving anti-viral therapy.Results: The data showed that the number of inpatients and outpatients within 10 years was increased by >2 folds; the number of patients with CHB was increased by >4 folds; the mortality of hospitalized patients decreased though it showed an increasing tendency; the number of patients with liver failure was reduced by 1/9 than that 10 years ago due to anti-viral therapy; the number of patients receiving anti-viral therapy with nucleoside drugs increased annually; in the patients with liver cirrhosis, patients without anti-viral therapy and those with anti-viral therapy accounted for 77.3% and 22.6%, respectively; from 2007 to 2013, the number of patients died of CHB hepatitis and liver cirrhosis after CHB was 1 585, in whom patients without anti-viral therapy and those with anti-viral therapy accounted for 63% and 37 %, respectively.Conclusion: The morbidity of CHB and liver cirrhosis shows an increasing tendency annually, and anti-viral therapy can significantly reduce the morbidity of liver failure, inhibit the rate of liver cirrhosis, and reduce the mortality of CHB and cirrhosis.
|
|---|
